ArticleACS nano2020
Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
Open access · greenAbstract read
In one paragraph
Article in ACS nano, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 156 citations in OpenAlex.
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.Signal transduction and targeted therapy · 2026Review
- Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Peptide Coacervates Promote Cytosolic Delivery of STING Agonists for Cancer Immunotherapy.Vaccines · 2026Article
- Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release.Molecular therapy. Advances · 2026Article
- A STING-activating biomimetic mineralized nanovaccine triggers robust anti-tumor immunity.Cancer immunology, immunotherapy : CII · 2026Article
- Advances in molecular innate immune regulation in the development and therapeutic strategies of allergic rhinitis vaccines.Frontiers in immunology · 2026Review
- Designer Solid Self-Emulsifying Nanovaccines Enable Dual Modulation of Dendritic Cells and T Cells for Potent Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.Advanced drug delivery reviews · 2025Review
- Emerging cGAS-STING Agonist-Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Fabrication of RIG-I-Activating Nanoparticles for Intratumoral Immunotherapy via Flash Nanoprecipitation.Molecular pharmaceutics · 2025Article
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Article
- Targeted Delivery of Personalized Cancer Vaccines Based on Antibody-Antigen Complexes.Vaccines · 2025Article
- Immune-modulative nano-gel-nano system for patient-favorable cancer therapy.Bioactive materials · 2025Article
- Nanoparticle-Based Strategies to Enhance the Efficacy of STING Activators in Cancer Immunotherapy.International journal of nanomedicine · 2025Review
- Designing multifunctional recombinant vaccines: an engineering strategy based on innovative epitope prediction-guided splicing.Theranostics · 2025Article
- Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response.Chem & bio engineering · 2024Article
- STING-Pathway Inhibiting Nanoparticles (SPINs) as a Platform for Treatment of Inflammatory Diseases.ACS applied bio materials · 2024Review
- A DNA-Modularized STING Agonist with Macrophage-Selectivity and Programmability for Enhanced Anti-Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Daniel ShaeDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Jessalyn J BaljonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Mohamed WehbeDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Plamen P ChristovVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.
Kyle W BeckerDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0003-1627-2724
Amrendra KumarDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Naveenchandra SuryadevaraDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Carcia S CarsonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Christian R PalmerDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0002-4184-0095
Frances C KnightDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Sebastian JoyceDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.ORCID 0000-0002-3183-1451
John T WilsonDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.ORCID 0000-0002-9144-2634
Vanderbilt University · USVA Tennessee Valley Healthcare System · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MIntegrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9MHead & Neck Cancer Neoantigen Characterization & Therapeutic TargetingR01DE027749 · NIDCR · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2018 to 2022
$2.3MMolecular Basis of CD1D and Natural Killer T Cell FunctionR01AI137082 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2019 to 2022
$2.1MEngineered Nanoparticles for Protective Subunit Vaccine Delivery and DiscoveryR21AI121626 · NIAID · VANDERBILT UNIVERSITY · PI WILSON, JOHN TANNER · 2016 to 2017
$418kVaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and AdjuvantI01BX001444 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2014 to 2022
–BLRD Research Career Scientist Award ApplicationIK6BX004595 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2019 to 2025
–BLRD VA I01 BX001444BLRD VA I01 BX006010BLRD VA IK6 BX004595NCI NIH HHS P30 CA068485NIAID NIH HHS R01 AI137082NIAID NIH HHS R21 AI121626NIDCR NIH HHS R01 DE027749NIDDK NIH HHS P30 DK058404NIDDK NIH HHS T32 DK101003
Abstract
Cancer vaccines targeting patient-specific neoantigens have emerged as a promising strategy for improving responses to immune checkpoint blockade. However, neoantigenic peptides are poorly immunogenic and inept at stimulating CD8
Indexed as
Cancer VaccinesNeoplasmsAnimalsAntigens, NeoplasmHumansInterferonsMicePeptidesAntigens, NeoplasmCancer VaccinesInterferonsPeptidescancer vaccineimmune checkpoint blockadeimmunotherapyneoantigenpolymer nanoparticle
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.